13F 机构持仓

Decheng Capital LLC

MENLO PARK CA · SEC CIK 0002010850

2026Q22026Q1 更早 9 个季度 🔒
$6.61亿2026Q1 申报市值
14持仓数
98.2%前十大占比 · 第一大 65.2%
0 / 5新建仓 / 清仓
申报市值走势$7.32亿2026Q2
26Q126Q2

付费方案可看全部 11 个季度的走势 🔒

前十大持仓 占组合比例

CGON 65.2%
NUVB 16.8%
UPB 3.7%
ACRS 2.3%
AARDVARK THERA 2.2%
Lyell Immunoph 2.1%
NAMS 1.6%
RCUS 1.6%
RVMD 1.4%
EQ 1.3%

2026Q1 买入最多 按季末市值估算

本季没有买入

2026Q1 卖出最多 按季末市值估算

RVMD 减仓-$1,035.71万
NAMS 减仓-$854.67万
CRINETICS PHARMA 清仓-$431.52万
UPB 减仓-$376.39万
KRYS 减仓-$258.32万

2026Q1 持仓明细 点表头排序

导出 CSV 🔒
代码名称市值 ▲占比股数变动股数变动估算买卖额操作
— CRINETICS PHARMACEUTICALS IN $00.00%0 -92,700-100.0% -$431.52万 清仓
AURA Aura Biosciences, Inc. $00.00%0 -360,483-100.0% -$196.46万 清仓
FDMT 4D MOLECULAR THERAPEUTICS IN $00.00%0 -44,311-100.0% -$33.23万 清仓
— Nuvation Bio Inc. $00.00%0 -646,057-100.0% -$21.32万 清仓
RZLT REZOLUTE INC $00.00%0 -59,900-100.0% -$14.14万 清仓
— Pyxis Oncology, Inc (formerly Apexigen) $47.71万0.07%326,810 00.0% — 不变
KRYS KRYSTAL BIOTECH INC $188.57万0.29%7,300 -10,000-57.8% -$258.32万 减仓
ZNTL Zentalis Pharmaceuticals Inc. $309.66万0.47%1,323,327 00.0% — 不变
— BeyondSpring Inc. $623.32万0.94%3,800,702 00.0% — 不变
EQ Equillium Inc. $889.46万1.34%4,447,308 00.0% — 不变
RVMD REVOLUTION MEDICINES INC(NSM) $909.29万1.37%93,500 -106,500-53.2% -$1,035.71万 减仓
RCUS Arcus Biosciences, Inc $1,032.09万1.56%477,819 -63,740-11.8% -$137.68万 减仓
NAMS NEWAMSTERDAM PHARMA CO NV $1,040.51万1.57%325,057 -267,000-45.1% -$854.67万 减仓
— Lyell Immunopharma, Inc. $1,388.25万2.10%692,050 00.0% — 不变
— AARDVARK THERAPEUTICS INC $1,476.82万2.23%3,917,299 00.0% — 不变
ACRS Aclaris Therapeutics, Inc. $1,515.65万2.29%4,041,736 00.0% — 不变
UPB Upstream Bio Inc. $2,452.38万3.71%2,724,868 -418,210-13.3% -$376.39万 减仓
NUVB Nuvation Bio Inc. $1.11亿16.84%25,954,439 00.0% — 不变
CGON CG ONCOLOGY INC $4.31亿65.21%6,371,669 00.0% — 不变